WeVote

Bill

Bill

SB 1013

Relating to: maintaining a supply of usable opioid antagonist at a public or private school and making an appropriation. (FE)

2025-2026 Regular Session Introduced by Dianne Hesselbein and 7 co-sponsors

Wisconsin schools must stock opioid antagonist (naloxone) with state funding to prevent overdose deaths among students during school hours.

Failed to pass pursuant to Senate Joint Resolution 1
0
WeVote Research Nonpartisan
Bill Summary · SB 1013

Legislative bill overview

SB 1013 requires public and private schools in Wisconsin to maintain a supply of opioid antagonist (such as naloxone/Narcan) on hand and includes state funding to support this requirement. The bill addresses the growing concern of opioid overdoses among school-age populations by ensuring emergency reversal medication is available during school hours.

Why is this important

Opioid overdoses have become a leading cause of death among adolescents and young adults, with overdose incidents increasingly occurring in school settings. Having readily available opioid antagonists can prevent fatal overdoses and save lives during the critical window between overdose onset and emergency responder arrival. This represents a public health intervention similar to requiring automated external defibrillators (AEDs) in schools.

Potential points of contention

  • Cost and implementation burden: Schools may face ongoing expenses for purchasing, training staff on administration, and replacing used doses, raising questions about adequacy of state appropriations
  • Liability and training concerns: Schools may worry about legal responsibility if naloxone is administered incorrectly or if they're seen as tacitly acknowledging a drug problem on campus
  • Privacy and stigma: Maintaining naloxone supplies might create concerns about identifying students with substance use disorders or inadvertently marking schools as having drug problems

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.